Role of hormonal risk factors in HER2-positive breast carcinomas

British Journal of Cancer

Volumn 88, Issue 7, 2003, Pages 1032-1034

  Balsari, A ^a   Casalini, P ^a   Bufalino, R ^a   Berrino, F ^a   Menard S ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Epidemiology; HER2; Hormone factor risk

Indexed keywords

ANTIBODY; HORMONE; TAMOXIFEN;

ADULT; AGE DETERMINATION; AGED; AGGRESSIVENESS; ARTICLE; BREAST CARCINOMA; CANCER CENTER; CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MENARCHE; MENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MENARCHE; MENOPAUSE; MIDDLE AGED; PARITY; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 0037692934     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600844     Document Type: Article

References (14)

1. Brinton LA, Schairer C, Hoover RN, Fraumeni JFJ (1988) Menstrual factors and risk of breast cancer. Cancer Invest 6: 245-254
2. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S (1996) c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708
3. Ferrero-Pous M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F (2000) Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 6: 4745-4754
4. Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15: 36-47
5. Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N (2002) HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8: 520-525
6. Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI (1999a) Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 55: 169-177
7. Ménard S, Valagussa P, Pilotti S, Biganzoli E, Boracchi P, Casalini P, Tomasic G, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G. (1999b) Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER2. Proc Am Soc Clin Oncol 18: 257
8. Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F, Pilotti S (1999) c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 80: 519-525
9. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446
10. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44-49
11. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. The Oncologist 3: 237-252
12. Ross JS, Fletcher JA (1999) HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112: S53-S67
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
14. Vatten LJ, Kvinnsland S (1992) Pregnancy-related factors and risk of breast cancer in a prospective study of 29,981 Norwegian women. Eur J Cancer 28A: 1148-1153